Potential role of probiotics in the management of gastric ulcer (Review)

Experimental and Therapeutic Medicine

Volumn 12, Issue 1, 2016, Pages 3-17

  Khoder, Ghalia ^a   Al Menhali, Asma A ^b   Al Yassir, Farah ^c   Karam, Sherif M ^c  

^a UNIVERSITY OF SHARJAH   (United Arab Emirates)

^b UNITED ARAB EMIRATES UNIVERSITY   (United Arab Emirates)

^c UNITED ARAB EMIRATES UNIVERSITY   (United Arab Emirates)

Author keywords

Gastric mucosa; Gastric mucosal barrier; Gastric ulcer; Gastric ulcer healing; Gastric ulcer prevention; Helicobacter pylori; Probiotics

Indexed keywords

EID: 84968919574     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2016.3293     Document Type: Review

References (202)

1. Tarnawski A, Ahluwalia A and Jones MK: Gastric cytoprotection beyond prostaglandins: Cellular and molecular mechanisms of gastroprotective and ulcer healing actions of antacids. Curr Pharm Des 19: 126-132, 2013.
2. Lau JY, Barkun A, Fan DM, Kuipers EJ, Yang YS and Chan FK: Challenges in the management of acute peptic ulcer bleeding. Lancet 381: 2033-2043, 2013.
3. Hwang JJ, Lee DH, Lee AR, Yoon H, Shin CM, Park YS and Kim N: Characteristics of gastric cancer in peptic ulcer patients with Helicobacter pylori infection. World J Gastroenterol 21: 4954-4960, 2015.
4. Taş İ, Ülger BV, Önder A, Kapan M and Bozdağ Z: Risk factors influencing morbidity and mortality in perforated peptic ulcer disease. Ulus Cerrahi Derg 31: 20-25, 2014.
5. Malfertheiner P: Helicobacter pylori infection-management from a European perspective. Dig Dis 32: 275-280, 2014.
6. Wallace JL, Syer S, Denou E, de Palma G, Vong L, McKnight W, Jury J, Bolla M, Bercik P, Collins SM, et al: Proton pump inhibitors exacerbate NSAID-induced small intestinal injury by inducing dysbiosis. Gastroenterology 141: 1314-1322.e5, 2011.
7. Karam SM and Forte JG: Inhibiting gastric H(+)-K(+)-ATPase activity by omeprazole promotes degeneration and production of parietal cells. Am J Physiol 266: G745-G758, 1994.
8. Ghotaslou R, Leylabadlo HE and Asl YM: Prevalence of antibiotic resistance in Helicobacter pylori: A recent literature review. World J Methodol 5: 164-174, 2015.
9. Howden CW, Chey WD and Vakil NB: Clinical rationale for confirmation testing after treatment of Helicobacter pylori infection: Implications of rising antibiotic resistance. Gastroenterol Hepatol (NY) 10 (7 Suppl 3): S1-S19, 2014.
10. Tarnawski A, Hollander D, Krause WJ, Dabros W, Stachura J and Gergely H: ‘Healed’ experimental gastric ulcers remain histologically and ultrastructurally abnormal. J Clin Gastroenterol 12 (Suppl 1): S139-S147, 1990.
11. Watanabe T, Higuchi K, Tominaga K, Fujiwara Y and Arakawa T: Acid regulates inflammatory response in a rat model of induction of gastric ulcer recurrence by interleukin 1beta. Gut 48: 774-781, 2001.
12. Arakawa T, Watanabe T, Tanigawa T, Tominaga K, Fujiwara Y and Morimoto K: Quality of ulcer healing in gastrointestinal tract: Its pathophysiology and clinical relevance. World J Gastroenterol 18: 4811-4822, 2012.
13. Groenen MJ, Kuipers EJ, Hansen BE and Ouwendijk RJ: Incidence of duodenal ulcers and gastric ulcers in a Western population: Back to where it started. Can J Gastroenterol 23: 604-608, 2009.
14. Sung JJ, Kuipers EJ and El-Serag HB: Systematic review: The global incidence and prevalence of peptic ulcer disease. Aliment Pharmacol Ther 29: 938-946, 2009.
15. Fujino S, Suzuki Y and Tanaka T: Cost-benefit analysis of medicinal treatment for gastric ulcers. Long-term model including healing and recurrence. Health Policy 5: 45-72, 1985.
16. Malfertheiner P, Chan FK and McColl KE: Peptic ulcer disease. Lancet 374: 1449-1461, 2009.
17. Hirayama F, Takagi S, Kusuhara H, Iwao E, Yokoyama Y and Ikeda Y: Induction of gastric ulcer and intestinal metaplasia in mongolian gerbils infected with Helicobacter pylori. J Gastroenterol 31: 755-757, 1996.
18. Wang GZ, Huang GP, Yin GL, Zhou G, Guo CJ, Xie CG, Jia BB and Wang JF: Aspirin can elicit the recurrence of gastric ulcer induced with acetic acid in rats. Cell Physiol Biochem 20: 205-212, 2007.
19. Hammadi M, Adi M, John R, Khoder GA and Karam SM: Dysregulation of gastric H,K-ATPase by cigarette smoke extract. World J Gastroenterol 15: 4016-4022, 2009.
20. Tarnawski AS: Cellular and molecular mechanisms of gastrointestinal ulcer healing. Dig Dis Sci 50 (Suppl 1): S24-S33, 2005.
21. Tarnawski A, Szabo IL, Husain SS and Soreghan B: Regeneration of gastric mucosa during ulcer healing is triggered by growth factors and signal transduction pathways. J Physiol Paris 95: 337-344, 2001.
22. Tarnawski AS and Ahluwalia A: Molecular mechanisms of epithelial regeneration and neovascularization during healing of gastric and esophageal ulcers. Curr Med Chem 19: 16-27, 2012.
23. Okamoto R, Yajima T, Yamazaki M, Kanai T, Mukai M, Okamoto S, Ikeda Y, Hibi T, Inazawa J and Watanabe M: Damaged epithelia regenerated by bone marrow-derived cells in the human gastrointestinal tract. Nat Med 8: 1011-1017, 2002.
24. Karam SM: Lineage commitment and maturation of epithelial cells in the gut. Front Biosci 4: D286-D298, 1999.
25. Helander HF and Poorkhalkali N: Parietal cell density during gastric ulcer healing in the rat. Scand J Gastroenterol 39: 20-26, 2004.
26. Farrell JJ, Taupin D, Koh TJ, Chen D, Zhao CM, Podolsky DK and Wang TC: TFF2/SP-deficient mice show decreased gastric proliferation, increased acid secretion, and increased susceptibility to NSAID injury. J Clin Invest 109: 193-204, 2002.
27. Liu L, Chiu PW, Lam PK, Poon CC, Lam CC, Ng EK and Lai PB: Effect of local injection of mesenchymal stem cells on healing of sutured gastric perforation in an experimental model. Br J Surg 102: e158-e168, 2015.
28. Chang Q, Yan L, Wang CZ, Zhang WH, Hu YZ and Wu BY: In vivo transplantation of bone marrow mesenchymal stem cells accelerates repair of injured gastric mucosa in rats. Chin Med J (Engl) 125: 1169-1174, 2012.
29. Maemura T, Shin M and Kinoshita M: Tissue engineering of the stomach. J Surg Res 183: 285-295, 2013.
30. Sato T and Clevers H: SnapShot: Growing organoids from stem cells. Cell 161: 1700-1700.e1, 2015.
31. Pulikkot S, Greish YE, Mourad AH and Karam SM: Establishment of a three-dimensional culture system of gastric stem cells supporting mucous cell differentiation using microfibrous polycaprolactone scaffolds. Cell Prolif 47: 553-563, 2014.
32. Elliott SN, Buret A, McKnight W, Miller MJ and Wallace JL: Bacteria rapidly colonize and modulate healing of gastric ulcers in rats. Am J Physiol 275: G425-G432, 1998.
33. Podolsky SH: Metchnikoff and the microbiome: Lancet 380: 1810-1811, 2012.
34. Lilly DM and Stillwell RH: Probiotics: Growth-promoting factors produced by microorganisms. Science 147: 747-748, 1965.
35. Hill C, Guarner F, Reid G, Gibson GR, Merenstein DJ, Pot B, Morelli L, Canani RB, Flint HJ, Salminen S, et al: Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol 11: 506-514, 2014.
36. Wallace TC, Guarner F, Madsen K, Cabana MD, Gibson G, Hentges E and Sanders ME: Human gut microbiota and its relationship to health and disease. Nutr Rev 69: 392-403, 2011.
37. Bezkorovainy A: Probiotics: Determinants of survival and growth in the gut. AmJ Clin Nutr 73 (Suppl 2): S399-S405, 2001.
38. Isolauri E, Sütas Y, Kankaanpää P, Arvilommi H and Salminen S: Probiotics: Effects on immunity. Am J Clin Nutr 73 (Suppl 2): S444-S450, 2001.
39. Hong WS, Chen YP and Chen MJ: The antiallergic effect of kefir lactobacilli. J Food Sci 75: H244-H253, 2010.
40. Cain AM and Karpa KD: Clinical utility of probiotics in inflammatory bowel disease. Altern Ther Health Med 17: 72-79, 2011.
41. Shyu PT, Oyong GG and Cabrera EC: Cytotoxicity of probiotics from Philippine commercial dairy products on cancer cells and the effect on expression of cfos and cjun early apoptotic-promoting genes and interleukin-1β and tumor necrosis factor-α proinflammatory cytokine genes. Biomed Res Int 2014: 491740, 2014.
42. Lam EK, Yu L, Wong HP, Wu WK, Shin VY, Tai EK, So WH, Woo PC and Cho CH: Probiotic Lactobacillus rhamnosus GG enhances gastric ulcer healing in rats. Eur J Pharmacol 565: 171-179, 2007.
43. Uchida M and Kurakazu K: Yogurt containing Lactobacillus gasseri OLL2716 exerts gastroprotective action against acute gastric lesion and antral ulcer in rats. J Pharmacol Sci 96: 84-90, 2004.
44. Uchida M, Shimizu K and Kurakazu K: Yogurt containing Lactobacillus gasseri OLL 2716 (LG21 yogurt) accelerated the healing of acetic acid-induced gastric ulcer in rats. Biosci Biotechnol Biochem 74: 1891-1894, 2010.
45. Singh PK and Kaur IP: Synbiotic (probiotic and ginger extract) loaded floating beads: A novel therapeutic option in an experimental paradigm of gastric ulcer. J Pharm Pharmacol 64: 207-217, 2012.
46. Singh PK, Deol PK and Kaur IP: Entrapment of Lactobacillus acidophilus into alginate beads for the effective treatment of cold restraint stress induced gastric ulcer. Food Funct 3: 83-90, 2012.
47. Dharmani P, De Simone C and Chadee K: The probiotic mixture VSL#3 accelerates gastric ulcer healing by stimulating vascular endothelial growth factor. PLoS One 8: 58671, 2013.
48. Lam EK, Tai EK, Koo MW, Wong HP, Wu WK, Yu L, So WH, Woo PC and Cho CH: Enhancement of gastric mucosal integrity by Lactobacillus rhamnosus GG. Life Sci 80: 2128-2136, 2007.
49. Timmerman HM, Koning CJ, Mulder L, Rombouts FM and Beynen AC: Monostrain, multistrain and multispecies probiotics-A comparison of functionality and efficacy. Int J Food Microbiol 96: 219-233, 2004.
50. Flatley EA, Wilde AM and Nailor MD: Saccharomyces boulardii for the prevention of hospital onset Clostridium difficile infection. J Gastrointestin Liver Dis 24: 21-24, 2015.
51. Girard P, Coppé MC, Pansart Y and Gillardin JM: Gastroprotective effect of Saccharomyces boulardii in a rat model of ibuprofen-induced gastric ulcer. Pharmacology 85: 188-193, 2010.
52. Sakarya S and Gunay N: Saccharomyces boulardii expresses neuraminidase activity selective for α2,3-linked sialic acid that decreases Helicobacter pylori adhesion to host cells. APMIS 122: 941-950, 2014.
53. Aragon G, Graham DB, Borum M and Doman DB: Probiotic therapy for irritable bowel syndrome. Gastroenterol Hepatol (NY) 6: 39-44, 2010.
54. Brenner DM, Moeller MJ, Chey WD and Schoenfeld PS: The utility of probiotics in the treatment of irritable bowel syndrome: A systematic review. Am J Gastroenterol 104: 1033-1050, 2009.
55. Moayyedi P, Ford AC, Talley NJ, Cremonini F, Foxx-Orenstein AE, Brandt LJ and Quigley EM: The efficacy of probiotics in the treatment of irritable bowel syndrome: A systematic review. Gut 59: 325-332, 2010.
56. Ki Cha B, Mun Jung S, Hwan Choi C, Song ID, Woong Lee H, Joon Kim H, Hyuk J, Kyung Chang S, Kim K, Chung WS and Seo JG: The effect of a multispecies probiotic mixture on the symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: A randomized, double-blind, placebo-controlled trial. J Clin Gastroenterol 46: 220-227, 2012.
57. Lyra A, Krogius-Kurikka L, Nikkilä J, Malinen E, Kajander K, Kurikka K, Korpela R and Palva A: Effect of a multispecies probiotic supplement on quantity of irritable bowel syndrome-related intestinal microbial phylotypes. BMC Gastroenterol 10: 110, 2010.
58. Fuochi V, Petronio GP, Lissandrello E and Furneri PM: Evaluation of resistance to low pH and bile salts of human Lactobacillus spp. isolates. Int J Immunopathol Pharmacol 28: 426-433, 2015.
59. Pochart P, Marteau P, Bouhnik Y, Goderel I, Bourlioux P and Rambaud JC: Survival of bifidobacteria ingested via fermented milk during their passage through the human small intestine: An in vivo study using intestinal perfusion. Am J Clin Nutr 55: 78-80, 1992.
60. Lankaputhra WEV and Shah NP: Survival of Lactobacillus acidophilus and Bifidobacterium in the presence of acid and bile salts. Cult Dairy Prod J 30: 2-7, 1995.
61. Costello M: Probiotic foods. In: Foodpro-93: International Food Processing Machinery and Technology Exhibition and Conference, Sydney Convention & Exhibition Centre, Australia, July 12-14 1993.
62. Clark PA, Cotton LN and Martin JH: Selection of Bifidobacterium spp. for use as dietary adjuncts in cultured dairy foods: II. Tolerance to simulated pH of human stomachs. Cult Dairy Prod J 28: 11-14, 1993.
63. Jacobsen CN, Rosenfeldt Nielsen V, Hayford AE, Møller PL, Michaelsen KF, Paerregaard A, Sandström B, Tvede M and Jakobsen M: Screening of probiotic activities of forty-seven strains of Lactobacillus spp. by in vitro techniques and evaluation of the colonization ability of five selected strains in humans. Appl Environ Microbiol 11: 4949-4956, 1999.
64. Lick S, Drescher K and Heller JK: Survival of Lactobacillus delbrueckii subsp. bulgaricus and Streptococcus thermophilus in the terminal ileum of fistulated Göttingen minipigs. Appl Environ Microbiol 67: 4137-4143, 2001.
65. Cotter PD and Hill C: Surviving the acid test: Responses of gram-positive bacteria to low pH. Microbiol Mol Biol Rev 67: 429-453, 2003.
66. Fortier LC, Tourdot-Maréchal R, Diviès C, Lee BH and Guzzo J: Induction of Oenococcus oeni H+-ATPase activity and mRNA transcription under acidic conditions. FEMS Microbiol Lett 222: 165-169, 2003.
67. Rius N, Solé M, Francis A and Lorén JG: Buffering capacity and membrane H+ conductance of lactic acid bacteria. FEMS Microbiol Lett 120: 291-296, 1994.
68. Charalampopoulos D, Pandiella SS and Webb C: Evaluation of the effect of malt, wheat and barley extracts on the viability of potentially probiotic lactic acid bacteria under acidic conditions. Int J Food Microbiol 82: 133-141, 2003.
69. Corcoran BM, Stanton C, Fitzgerald GF and Ross RP: Survival of probiotic lactobacilli in acidic environments is enhanced in the presence of metabolizable sugars. Appl Environ Microbiol 71: 3060-3067, 2005.
70. Haghshenas B, Abdullah N, Nami Y, Radiah D, Rosli R and Yari Khosroushahi A: Microencapsulation of probiotic bacteria Lactobacillus plantarum 15HN using alginate-psyllium-fenugreek polymeric blends. J Appl Microbiol 118: 1048-1057, 2015.
71. Chen S, Zhao Q, Ferguson LR, Shu Q, Weir I and Garg S: Development of a novel probiotic delivery system based on microencapsulation with protectants. Appl Microbiol Biotechnol 93: 1447-1457, 2012.
72. Kailasapathy K: Microencapsulation of probiotic bacteria: Technology and potential applications. Curr Issues Intest Microbiol 3: 39-48, 2002.
73. Villena MJ, Lara-Villoslada F, Martínez MA and Hernández ME: Development of gastro-resistant tablets for the protection and intestinal delivery of Lactobacillus fermentum CECT 5716. Int J Pharm 487: 314-319, 2015.
74. Mei L, He F, Zhou RQ, Wu CD, Liang R, Xie R, Ju XJ, Wang W and Chu LY: Novel intestinal-targeted Ca-alginate-based carrier for pH-responsive protection and release of lactic acid bacteria. ACS Appl Mater Interfaces 6: 5962-5970, 2014.
75. Zhao Q, Lee SJ, Mutukumira AN, Maddox I and Shu Q: Viability and delivery of immobilised Lactobacillus reuteri DPC16 within calcium alginate gel systems during sequential passage through simulated gastrointestinal fluids. Benef Microbes 2: 129-138, 2011.
76. Adams CA: The probiotic paradox: Live and dead cells are biological response modifiers. Nutr Res Rev 23: 37-46, 2010.
77. Sashihara T, Sueki N and Ikegami S: An analysis of the effectiveness of heat-killed lactic acid bacteria in alleviating allergic diseases. J Dairy Sci 89: 2846-2855, 2006.
78. Zhang L, Nan L, Caicedo R and Neu J: Alive and dead Lactobacillus rhamnosus GG decrease tumor necrosis factor-alpha-induced interleukin-8 production in Caco-2 cells. J Nutr 135: 1752-1756, 2005.
79. Taverniti V and Guglielmetti S: The immunomodulatory properties of probiotic microorganisms beyond their viability (ghost probiotics: Proposal of paraprobiotic concept). Genes Nutr 6: 261-274, 2011.
80. Sakai Y, Tsukahara T, Bukawa W, Matsubara N and Ushida K: Cell preparation of Enterococcus faecalis strain EC-12 prevents vancomycin-resistant enterococci colonization in the cecum of newly hatched chicks. Poult Sci 85: 273-277, 2006.
81. Marin ML, Lee JH, Murtha J, Ustunol Z and Pestka JJ: Differential cytokine production in clonal macrophage and T-cell lines cultured with bifidobacteria. J Dairy Sci 80: 2713-2720, 1997.
82. Wagner RD, Pierson C, Warner T, Dohnalek M, Hilty M and Balish E: Probiotic effects of feeding heat-killed Lactobacillus acidophilus and Lactobacillus casei to Candida albicans-colonized immunodeficient mice. J Food Prot 63: 638-644, 2000.
83. Rachmilewitz D, Katakura K, Karmeli F, Hayashi T, Reinus C, Rudensky B, Akira S, Takeda K, Lee J, Takabayashi K and Raz E: Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis. Gastroenterology 126: 520-528, 2004.
84. Orlando A, Refolo MG, Messa C, Amati L, Lavermicocca P, Guerra V and Russo F: Antiproliferative and proapoptotic effects of viable or heat-killed Lactobacillus paracasei IMPC2.1 and Lactobacillus rhamnosus GG in HGC-27 gastric and DLD-1 colon cell lines. Nutr Cancer 64: 1103-1111, 2012.
85. Sanders ME, Guarner F, Guerrant R, Holt PR, Quigley EM, Sartor RB, Sherman PM and Mayer EA: An update on the use and investigation of probiotics in health and disease. Gut 62: 787-796, 2013.
86. Marchesi JR, Adams DH, Fava F, Hermes GD, Hirschfield GM, Hold G, Quraishi MN, Kinross J, Smidt H, Tuohy KM, et al: The gut microbiota and host health: A new clinical frontier. Gut 65: 330-339, 2016.
87. Kumar M, Nagpal R, Kumar R, Hemalatha R, Verma V, Kumar A, Chakraborty C, Singh B, Marotta F, Jain S and Yadav H: Cholesterol-lowering probiotics as potential biotherapeutics for metabolic diseases. Exp Diabetes Res 2012: 902917, 2012.
88. Tsai TY, Chen LY and Pan TM: Effect of probiotic-fermented, genetically modified soy milk on hypercholesterolemia in hamsters. J Microbiol Immunol Infect 47: 1-8, 2014.
89. Pereira DI and Gibson GR: Cholesterol assimilation by lactic acid bacteria and bifidobacteria isolated from the human gut. Appl Environ Microbiol 68: 4689-4693, 2002.
90. Kadooka Y, Sato M, Imaizumi K, Ogawa A, Ikuyama K, Akai Y, Okano M, Kagoshima M and Tsuchida T: Regulation of abdominal adiposity by probiotics (Lactobacillus gasseri SBT2055) in adults with obese tendencies in a randomized controlled trial. Eur J Clin Nutr 64: 636-643, 2010.
91. Yoda K, Sun X, Kawase M, Kubota A, Miyazawa K, Harata G, Hosoda M, Hiramatsu M, He F and Zemel MB: A combination of probiotics and whey proteins enhances anti-obesity effects of calcium and dairy products during nutritional energy restriction in aP2-agouti transgenic mice. Br J Nutr 113: 1689-1696, 2015.
92. Kim SH, Huh CS, Choi ID, Jeong JW, Ku HK, Ra JH, Kim TY, Kim GB, Sim JH and Ahn YT: The anti-diabetic activity of Bifidobacterium lactis HY8101 in vitro and in vivo. J Appl Microbiol 117: 834-845, 2014.
93. Moroti C, Souza Magri LF, de Rezende Costa M, Cavallini DC and Sivieri K: Effect of the consumption of a new symbiotic shake on glycemia and cholesterol levels in elderly people with type 2 diabetes mellitus. Lipids Health Dis 11: 29, 2012.
94. Huang Y, Wang J, Quan G, Wang X, Yang L and Zhong L: Lactobacillus acidophilus ATCC 4356 prevents atherosclerosis via inhibition of intestinal cholesterol absorption in apolipoprotein E-knockout mice. Appl Environ Microbiol 80: 7496-7504, 2014.
95. Aihara K, Kajimoto O, Hirata H, Takahashi R and Nakamura Y: Effect of powdered fermented milk with Lactobacillus helveticus on subjects with high-normal blood pressure or mild hypertension. J Am Coll Nutr 24: 257-265, 2005.
96. Rashid SK, Idris-Khodja N, Auger C, Alhosin M, Boehm N, Oswald-Mammosser M and Schini-Kerth VB: Probiotics (VSL#3) prevent endothelial dysfunction in rats with portal hypertension: Role of the angiotensin system. PLoS One 9: e97458, 2014.
97. Fotiadis CI, Stoidis CN, Spyropoulos BG and Zografos ED: Role of probiotics, prebiotics and synbiotics in chemoprevention for colorectal cancer. World J Gastroenterol 14: 6453-6457, 2008.
98. Sobhani I, Amiot A, Le Baleur Y, Levy M, Auriault ML, Van Nhieu JT and Delchier JC: Microbial dysbiosis and colon carcinogenesis: Could colon cancer be considered a bacteria-related disease? Therap Adv Gastroenterol 6: 215-229, 2013.
99. Zhang M, Fan X, Fang B, Zhu C, Zhu J and Ren F: Effects of Lactobacillus salivarius Ren on cancer prevention and intestinal microbiota in 1,2-dimethylhydrazine-induced rat model. J Microbiol 53: 398-405, 2015.
100. Chen ZF, Ai LY, Wang JL, Ren LL, Yu YN, Xu J, Chen HY, Yu J, Li M, Qin WX, et al: Probiotics Clostridium butyricum and Bacillus subtilis ameliorate intestinal tumorigenesis. Future Microbiol 10: 1433-1445, 2015.
101. Russo F, Linsalata M and Orlando A: Probiotics against neoplastic transformation of gastric mucosa: Effects on cell proliferation and polyamine metabolism. World J Gastroenterol 20: 13258-13272, 2014.
102. Cousin FJ, Jouan-Lanhouet S, Dimanche-Boitrel MT, Corcos L and Jan G: Milk fermented by Propionibacterium freudenreichii induces apoptosis of HGT-1 human gastric cancer cells. PLoS One 7: e31892, 2012.
103. Linsalata M, Cavallini A, Messa C, Orlando A, Refolo MG and Russo F: Lactobacillus rhamnosus GG influences polyamine metabolism in HGC-27 gastric cancer cell line: A strategy toward nutritional approach to chemoprevention of gastric cancer. Curr Pharm Des 16: 847-853, 2010.
104. Haghshenas B, Abdullah N, Nami Y, Radiah D, Rosli R and Khosroushahi AY: Different effects of two newly-isolated probiotic Lactobacillus plantarum 15HN and Lactococcus lactis subsp. Lactis 44Lac strains from traditional dairy products on cancer cell lines. Anaerobe 30: 51-59, 2014.
105. Chitapanarux I, Chitapanarux T, Traisathit P, Kudumpee S, Tharavichitkul E and Lorvidhaya V: Randomized controlled trial of live Lactobacillus acidophilus plus Bifidobacterium bifidum in prophylaxis of diarrhea during radiotherapy in cervical cancer patients. Radiat Oncol 5: 31, 2010.
106. Osterlund P, Ruotsalainen T, Korpela R, Saxelin M, Ollus A, Valta P, Kouri M, Elomaa I and Joensuu H: Lactobacillus supplementation for diarrhoea related to chemotherapy of colorectal cancer: A randomised study. Br J Cancer 97: 1028-1034, 2007.
107. Crouzet L, Rigottier-Gois L and Serror P: Potential use of probiotic and commensal bacteria as non-antibiotic strategies against vancomycin-resistant enterococci. FEMS Microbiol Lett 362: fnv012, 2015.
108. Gill EE, Franco OL and Hancock RE: Antibiotic adjuvants: Diverse strategies for controlling drug-resistant pathogens. Chem Biol Drug Des 85: 56-78, 2015.
109. Cano-Garrido O, Seras-Franzoso J and Garcia-Fruitós E: Lactic acid bacteria: Reviewing the potential of a promising delivery live vector for biomedical purposes. Microb Cell Fact 14: 137, 2015.
110. Mohamadzadeh M and Owen JL: Reprogramming intestinal immunity is the answer to induced pathogenic inflammation. Immunotherapy 3: 1415-1417, 2011.
111. Wells JM and Mercenier A: Mucosal delivery of therapeutic and prophylactic molecules using lactic acid bacteria. Nat Rev Microbiol 6: 349-362, 2008.
112. Bermúdez-Humarán LG: Lactococcus lactis as a live vector for mucosal delivery of therapeutic proteins. Hum Vaccin 5: 264-267, 2009.
113. Marelli B, Perez AR, Banchio C, de Mendoza D and Magni C: Oral immunization with live Lactococcus lactis expressing rotavirus VP8 subunit induces specific immune response in mice. J Virol Methods 175: 28-37, 2011.
114. Konturek PC, Sliwowski Z, Koziel J, Ptak-Belowska A, Burnat G, Brzozowski T and Konturek SJ: Probiotic bacteria Escherichia coli strain Nissle 1917 attenuates acute gastric lesions induced by stress. J Physiol Pharmacol 60 (Suppl 6): S41-S48, 2009.
115. Spivak MIa, Lazarenko LM, Falalieieva TM, Virchenko OV and Neporada KS: Prophylactic effect of probiotic strains Bifidobacterium animalis VKL and VKB on stress-induced lesions in the gastric mucosa of rats. Fiziol Zh 59: 23-30, 2013 (In Ukrainian).
116. Nagaoka M, Hashimoto S, Watanabe T, Yokokura T and Mori Y: Anti-ulcer effects of lactic acid bacteria and their cell wall polysaccharides. Biol Pharm Bull 17: 1012-1017, 1994.
117. Viggiano D, Ianiro G, Vanella G, Bibbò S, Bruno G, Simeone G and Mele G: Gut barrier in health and disease: Focus on childhood. Eur Rev Med Pharmacol Sci 19: 1077-1085, 2015.
118. Laine L, Takeuchi K and Tarnawski A: Gastric mucosal defense and cytoprotection: Bench to bedside. Gastroenterology 135: 41-60, 2008.
119. Takeeda M, Hayashi Y, Yamato M, Murakami M and Takeuchi K: Roles of endogenous prostaglandins and cyclooxygenase izoenzymes in mucosal defense of inflamed rat stomach. J Physiol Pharmacol 55: 193-205, 2004.
120. Boirivant M and Strober W: The mechanism of action of probiotics. Curr Opin Gastroenterol 23: 679-692, 2007.
121. Vieira AT, Teixeira MM and Martins FS: The role of probiotics and prebiotics in inducing gut immunity. Front Immunol 4: 445, 2013.
122. Jones SE and Versalovic J: Probiotic Lactobacillus reuteri biofilms produce antimicrobial and anti-inflammatory factors. BMC Microbiol 9: 35, 2009.
123. Coman MM, Verdenelli MC, Cecchini C, Silvi S, Orpianesi C, Boyko N and Cresci A: In vitro evaluation of antimicrobial activity of Lactobacillus rhamnosus IMC 501®, Lactobacillus paracasei IMC 502® and SYNBIO® against pathogens. J Appl Microbiol 117: 518-527, 2014.
124. Bernet MF, Brassart D, Neeser JR and Servin AL: Lactobacillus acidophilus LA 1 binds to cultured human intestinal cell lines and inhibits cell attachment and cell invasion by enterovirulent bacteria. Gut 35: 483-489, 1994.
125. Mukai T, Asasaka T, Sato E, Mori K, Matsumoto M and Ohori H: Inhibition of binding of Helicobacter pylori to the glycolipid receptors by probiotic Lactobacillus reuteri. FEMS Immunol Med Microbiol 32: 105-110, 2002.
126. Lin YP, Thibodeaux CH, Peña JA, Ferry GD and Versalovic J: Probiotic Lactobacillus reuteri suppress proinflammatory cytokines via c-Jun. Inflamm Bowel Dis 14: 1068-1083, 2008.
127. Takagi A, Matsuzaki T, Sato M, Nomoto K, Morotomi M and Yokokura T: Enhancement of natural killer cytotoxicity delayed murine carcinogenesis by a probiotic microorganism. Carcinogenesis 22: 599-605, 2001.
128. Haller D, Bode C, Hammes WP, Pfeifer AM, Schiffrin EJ and Blum S: Non-pathogenic bacteria elicit a differential cytokine response by intestinal epithelial cell/leucocyte co-cultures. Gut 47: 79-87, 2000.
129. Borchers AT, Selmi C, Meyers FJ, Keen CL and Gershwin ME: Probiotics and immunity. J Gastroenterol 44: 26-46, 2009.
130. Madsen K, Cornish A, Soper P, McKaigney C, Jijon H, Yachimec C, Doyle J, Jewell L and De Simone C: Probiotic bacteria enhance murine and human intestinal epithelial barrier function. Gastroenterology 121: 580-591, 2001.
131. Gotteland M, Cruchet S and Verbeke S: Effect of Lactobacillus ingestion on the gastrointestinal mucosal barrier alterations induced by indomethacin in humans. Aliment Pharmacol Ther 15: 11-17, 2001.
132. Rao RK and Samak G. Protection and Restitution of Gut Barrier by Probiotics: Nutritional and clinical implications. Curr Nutr Food Sci 9: 99-107, 2013.
133. Gomi A, Harima-Mizusawa N, Shibahara-Sone H, Kano M, Miyazaki K and Ishikawa F: Effect of Bifidobacterium bifidum BF-1 on gastric protection and mucin production in an acute gastric injury rat model. J Dairy Sci 96: 832-837, 2013.
134. Dai C, Zhao DH and Jiang M: VSL#3 probiotics regulate the intestinal epithelial barrier in vivo and in vitro via the p38 and ERK signaling pathways. Int J Mol Med 29: 202-208, 2012.
135. Mennigen R, Nolte K, Rijcken E, Utech M, Loeffler B, Senninger N and Bruewer M: Probiotic mixture VSL#3 protects the epithelial barrier by maintaining tight junction protein expression and preventing apoptosis in a murine model of colitis. Am J Physiol Gastrointest Liver Physiol 296: G1140-G1149, 2009.
136. Wang FY, Liu JM, Luo HH, Liu AH and Jiang Y: Potential protective effects of Clostridium butyricum on experimental gastric ulcers in mice. World J Gastroenterol 21: 8340-8351, 2015.
137. Virchenko OV, Falalyeyeva TM, Beregova TV, Spivak MY, Lazarenko LM and Demchenko OM: Effects of mono-, poly-and composite probiotics on the ulceration caused by restraint stress. Fiziol Zh 61: 35-41, 2015 (In Ukrainian).
138. Virchenko OV, Falalyeyeva TM, Beregova TV and Maryana SY: The multistrain probiotic enhances the healing process of stress-induced lesions of the gastric mucosa of rats. RJPBCS 6: 249, 2015.
139. Wang JY, Yamasaki S, Takeuchi K and Okabe S: Delayed healing of acetic acid-induced gastric ulcers in rats by indomethacin. Gastroenterology 96: 393-402, 1989.
140. Santucci L, Fiorucci S, Di Matteo FM and Morelli A: Role of tumor necrosis factor alpha release and leukocyte margination in indomethacin-induced gastric injury in rats. Gastroenterology 108: 393-401, 1995.
141. Yoshikawa T, Takano H, Naito Y, Oyamada H, Ueda S and Kondo M: Augmentative effects of tumor necrosis factor-alpha (human, natural type) on polymorphonuclear leukocyte-derived superoxide generation induced by various stimulants. Int J Immunopharmacol 14: 1391-1398, 1992.
142. Senol A, Işler M, Karahan AG, Kiliç GB, Kuleaşan H, Gören I, Saritaş U, Kaya S, Cırış M, Aktürk O, et al: Effect of probiotics on aspirin-induced gastric mucosal lesions. Turk J Gastroenterol 22: 18-26, 2011.
143. Senol A, Isler M, Karahan AG, Kilic GB, Kuleasan H, Kaya S, Keskin M, Goren I, Saritas U, Aridogan BC and Delibas N: Preventive effect of probiotics and α-tocopherol on ethanol-induced gastric mucosal injury in rats. J Med Food 14: 173-179, 2011.
144. Allen A and Pearson JP: Mucus glycoproteins of the normal gastrointestinal tract. Eur J Gastroenterol Hepatol 5: 193-199, 1993.
145. Wong WM, Poulsom R and Wright NA: Trefoil peptides. Gut 44: 890-895, 1999.
146. Phillipson M, Johansson ME, Henriksnäs J, Petersson J, Gendler SJ, Sandler S, Persson AE, Hansson GC and Holm L: The gastric mucus layers: Constituents and regulation of accumulation. Am J Physiol Gastrointest Liver Physiol 295: G806-G812, 2008.
147. Corfield AP, Carroll D, Myerscough N and Probert CS: Mucins in the gastrointestinal tract in health and disease. Front Biosci 6: D1321-D1357, 2001.
148. Singh PK and Hollingsworth MA: Cell surf ace-associated mucins in signal transduction. Trends Cell Biol 16: 467-476, 2006.
149. Karam SM, Tomasetto C and Rio MC: Trefoil factor 1 is required for the commitment programme of mouse oxyntic epithelial progenitors. Gut 53: 1408-1415, 2004.
150. Ren JL, Luo JY, Lu YP, Wang L and Shi HX: Relationship between trefoil factor 1 expression and gastric mucosa injuries and gastric cancer. World J Gastroenterol 11: 2674-2677, 2005.
151. Fu T, Kalbacher H and Hoffmann W: TFF1 is differentially expressed in stationary and migratory rat gastric epithelial cells (RGM-1) after in vitro wounding: Influence of TFF1 RNA interference on cell migration. Cell Physiol Biochem 32: 997-1010, 2013.
152. Atuma C, Strugala V, Allen A and Holm L: The adherent gastrointestinal mucus gel layer: Thickness and physical state in vivo. Am J Physiol Gastrointest Liver Physiol 280: G922-G929, 2001.
153. Kaunitz JD: Barrier function of gastric mucus. Keio J Med 2: 63-68, 1999.
154. Mattar AF, Teitelbaum DH, Drongowski RA, Yongyi F, Harmon CM and Coran AG: Probiotics up-regulate MUC-2 mucin gene expression in a Caco-2 cell-culture model. Pediatr Surg Int 18: 586-590, 2002.
155. Kim Y, Kim SH, Whang KY, Kim YJ and Oh S: Inhibition of Escherichia coli O157:H7 attachment by interactions between lactic acid bacteria and intestinal epithelial cells. J Microbiol Biotechnol 18: 1278-1285, 2008.
156. Otte JM and Podolsky DK: Functional modulation of enterocytes by gram-positive and gram-negative microorganisms. Am J Physiol Gastrointest Liver Physiol 286: G613-G626, 2004.
157. Caballero-Franco C, Keller K, De Simone C and Chadee K: The VSL#3 probiotic formula induces mucin gene expression and secretion in colonic epithelial cells. Am J Physiol Gastrointest Liver Physiol 292: G315-G322, 2007.
158. Ouwehand AC, Salminen S, Tölkkö S, Roberts P, Ovaska J and Salminen E: Resected human colonic tissue: New model for characterizing adhesion of lactic acid bacteria. Clin Diagn Lab Immunol 9: 184-186, 2002.
159. Nishiyama K, Nakamata K, Ueno S, Terao A, Aryantini NP, Sujaya IN, Fukuda K, Urashima T, Yamamoto Y and Mukai T: Adhesion properties of Lactobacillus rhamnosus mucus-binding factor to mucin and extracellular matrix proteins. Biosci Biotechnol Biochem 79: 271-279, 2015.
160. Karam SM and Leblond CP: Dynamics of epithelial cells in the corpus of the mouse stomach. I.dentification of proliferative cell types and pinpointing of the stem cell. Anat Rec 236: 259-279, 1993.
161. Karam SM, Straiton T, Hassan WM and Leblond CP: Defining epithelial cell progenitors in the human oxyntic mucosa. Stem Cells 21: 322-336, 2003.
162. Karam SM: A focus on parietal cells as a renewing cell population. World J Gastroenterol 16: 538-546, 2010.
163. Risau W: Mechanisms of angiogenesis. Nature 386: 671-674, 1997.
164. Taketani Y, Kinugasa K, Kitajima R, Nishiumi S, Ashida H, Nakamura H, Fujita T, Kanzaki K, Masutani H and Yodoi J: Protective effects of oral administration of yeast thioredoxin against gastric mucosal injury. Biosci Biotechnol Biochem 78: 1221-1230, 2014.
165. Schöttker B, Adamu MA, Weck MN and Brenner H: Helicobacter pylori infection is strongly associated with gastric and duodenal ulcers in a large prospective study. Clin Gastroenterol Hepatol 10: 487-493.e1, 2012.
166. Cover TL and Blaser MJ: Helicobacter pylori in health and disease. Gastroenterology 136: 1863-1873, 2009.
167. Vergara M, Catalán M, Gisbert JP and Calvet X: Meta-analysis: Role of Helicobacter pylori eradication in the prevention of peptic ulcer in NSAID users. Aliment Pharmacol Ther 21: 1411-1418, 2005.
168. Malfertheiner P, Selgrad M and Bornschein J. Helicobacter pylori: Clinical management. Curr Opin Gastroenterol 28: 608-614, 2012.
169. Giorgio F, Principi M, De Francesco V, Zullo A, Losurdo G, Di Leo A and Ierardi E: Primary clarithromycin resistance to Helicobacter pylori: Is this the main reason for triple therapy failure? World J Gastrointest Pathophysiol 4: 43-46, 2013.
170. Graham DY and Fischbach L: Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut 59: 1143-1153, 2010.
171. Papastergiou V, Georgopoulos SD and Karatapanis S: Treatment of Helicobacter pylori infection: Meeting the challenge of antimicrobial resistance. World J Gastroenterol 20: 9898-9911, 2014.
172. Tongtawee T, Dechsukhum C, Leeanansaksiri W, Kaewpitoon S, Kaewpitoon N, Loyd RA, Matrakool L and Panpimanmas S: Improved Helicobacter pylori eradication rate of tailored triple therapy by adding Lactobacillus delbrueckii and Streptococcus thermophilus in northeast region of Thailand: A prospective randomized controlled clinical trial. Gastroenterol Res Pract 2015: 518018, 2015.
173. Johnson-Henry KC, Mitchell DJ, Avitzur Y, Galindo-Mata E, Jones NL and Sherman PM: Probiotics reduce bacterial colonization and gastric inflammation in H. pylori-infected mice. Dig Dis Sci 49: 1095-1102, 2004.
174. Sheu BS, Wu JJ, Lo CY, Wu HW, Chen JH, Lin YS and Lin MD: Impact of supplement with Lactobacillus-and Bifidobacterium-containing yogurt on triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther 16: 1669-1675, 2002.
175. Ushiyama A, Tanaka K, Aiba Y, Shiba T, Takagi A, Mine T and Koga Y: Lactobacillus gasseri OLL2716 as a probiotic in clarithromycin-resistant Helicobacter pylori infection. J Gastroenterol Hepatol 18: 986-991, 2003.
176. Chenoll E, Casinos B, Bataller E, Astals P, Echevarría J, Iglesias JR, Balbarie P, Ramón D and Genovés S: Novel probiotic Bifidobacterium bifidum CECT 7366 strain active against the pathogenic bacterium Helicobacter pylori. Appl Environ Microbiol 77: 1335-1343, 2011.
177. Gotteland M and Cruchet S: Suppressive effect of frequent ingestion of Lactobacillus johnsonii La1 on Helicobacter pylori colonization in asymptomatic volunteers. J Antimicrob Chemother 51: 1317-1319, 2003.
178. Kabir AM, Aiba Y, Takagi A, Kamiya S, Miwa T and Koga Y: Prevention of Helicobacter pylori infection by lactobacilli in a gnotobiotic murine model. Gut 41: 49-55, 1997.
179. Lesbros-Pantoflickova D, Corthésy-Theulaz I and Blum AL: Helicobacter pylori and probiotics. J Nutr 137 (3 Suppl 2): S812-S818, 2007.
180. Ruggiero P: Use of probiotics in the fight against Helicobacter pylori. World J Gastrointest Pathophysiol 5: 384-391, 2014.
181. Yang YJ and Sheu BS: Probiotics-containing yogurts suppress Helicobacter pylori load and modify immune response and intestinal microbiota in the Helicobacter pylori-infected children. Helicobacter 17: 297-304, 2012.
182. Sgouras D, Maragkoudakis P, Petraki K, Martinez-Gonzalez B, Eriotou E, Michopoulos S, Kalantzopoulos G, Tsakalidou E and Mentis A: In vitro and in vivo inhibition of Helicobacter pylori by Lactobacillus casei strain Shirota. Appl Environ Microbiol 70: 518-526, 2004.
183. Aiba Y, Nakano Y, Koga Y, Takahashi K and Komatsu Y: A highly acid-resistant novel strain of Lactobacillus johnsonii No. 1088 has antibacterial activity, including that against Helicobacter pylori, and inhibits gastrin-mediated acid production in mice. Microbiologyopen 4: 465-474, 2015.
184. Isobe H, Nishiyama A, Takano T, Higuchi W, Nakagawa S, Taneike I, Fukushima Y and Yamamoto T: Reduction of overall Helicobacter pylori colonization levels in the stomach of Mongolian gerbil by Lactobacillus johnsonii La1 (LC1) and its in vitro activities against H. pylori motility and adherence. Biosci Biotechnol Biochem 76: 850-852, 2012.
185. Hsieh PS, Tsai YC, Chen YC, Teh SF, Ou CM and King VA: Eradication of Helicobacter pylori infection by the probiotic strains Lactobacillus johnsonii MH-68 and L. salivarius ssp. salicinius AP-32. Helicobacter 17: 466-477, 2012.
186. Chen X, Liu XM, Tian F, Zhang Q, Zhang HP, Zhang H and Chen W: Antagonistic activities of lactobacilli against Helicobacter pylori growth and infection in human gastric epithelial cells. J Food Sci 77: M9-M14, 2012.
187. Mack DR, Ahrne S, Hyde L, Wei S and Hollingsworth MA: Extracellular MUC3 mucin secretion follows adherence of Lactobacillus strains to intestinal epithelial cells in vitro. Gut 52: 827-833, 2003.
188. Thiraworawong T, Spinler JK, Werawatganon D, Klaikeaw N, Venable SF, Versalovic J and Tumwasorn S: Anti-inflammatory properties of gastric-derived Lactobacillus plantarum XB7 in the context of Helicobacter pylori infection. Helicobacter 19: 144-155, 2014.
189. Hwang SW, Kim N, Kim JM, Huh CS, Ahn YT, Park SH, Shin CM, Park JH, Lee MK, Nam RH, et al: Probiotic suppression of the H. pylori-induced responses by conjugated linoleic acids in a gastric epithelial cell line. Prostaglandins Leukot Essent Fatty Acids 86: 225-231, 2012.
190. Kim JM, Kim JS, Kim YJ, Oh YK, Kim IY, Chee YJ, Han JS and Jung HC: Conjugated linoleic acids produced by Lactobacillus dissociates IKK-gamma and Hsp90 complex in Helicobacter pylori-infected gastric epithelial cells. Lab Invest 88: 541-552, 2008.
191. Lee JS, Paek NS, Kwon OS and Hahm KB: Anti-inflammatory actions of probiotics through activating suppressor of cytokine signaling (SOCS) expression and signaling in Helicobacter pylori infection: A novel mechanism. J Gastroenterol Hepatol 25: 194-202, 2010.
192. Mehling H and Busjahn A: Non-viable Lactobacillus reuteri DSMZ 17648 (Pylopass™) as a new approach to Helicobacter pylori control in humans. Nutrients 5: 3062-3073, 2013.
193. Holz C, Busjahn A, Mehling H, Arya S, Boettner M, Habibi H and Lang C: Significant reduction in Helicobacter pylori load in humans with non-viable Lactobacillus reuteri DSM17648: A pilot study. Probiotics Antimicrob Proteins 7: 91-100, 2015.
194. Hauser G, Salkic N, Vukelic K, JajacKnez A and Stimac D: Probiotics for standard triple Helicobacter pylori eradication: A randomized, double-blind, placebo-controlled trial. Medicine (Baltimore) 94: e685, 2015.
195. Francavilla R, Polimeno L, Demichina A, Maurogiovanni G, Principi B, Scaccianoce G, Ierardi E, Russo F, Riezzo G, Di Leo A, et al: Lactobacillus reuteri strain combination in Helicobacter pylori infection: A randomized, double-blind, placebo-controlled study. J Clin Gastroenterol 48: 407-413, 2014.
196. Pantoflickova D, Corthésy-Theulaz I, Dorta G, Stolte M, Isler P, Rochat F, Enslen M and Blum AL: Favourable effect of regular intake of fermented milk containing Lactobacillus johnsonii on Helicobacter pylori associated gastritis. Aliment Pharmacol Ther 18: 805-813, 2003.
197. Michetti P, Dorta G, Wiesel PH, Brassart D, Verdu E, Herranz M, Felley C, Porta N, Rouvet M, Blum AL and Corthésy-Theulaz I: Effect of whey-based culture supernatant of Lactobacillus acidophilus (johnsonii) La1 on Helicobacter pylori infection in humans. Digestion 60: 203-209, 1999.
198. Szajewska H, Horvath A and Piwowarczyk A: Meta-analysis: The effects of Saccharomyces boulardii supplementation on Helicobacter pylori eradication rates and side effects during treatment. Aliment Pharmacol Ther 32: 1069-1079, 2010.
199. Zou J, Dong J and Yu X: Meta-analysis: Lactobacillus containing quadruple therapy versus standard triple first-line therapy for Helicobacter pylori eradication. Helicobacter 14: 97-107, 2009.
200. Hamilton-Miller JM: The role of probiotics in the treatment and prevention of Helicobacter pylori infection. Int J Antimicrob Agents 22: 360-366, 2003.
201. Patel A, Shah N and Prajapati JB: Clinical application of probiotics in the treatment of Helicobacter pylori infection-a brief review. J Microbiol Immunol Infect 47: 429-437, 2014.
202. Shane AL, Cabana MD, Vidry S, Merenstein D, Hummelen R, Ellis CL, Heimbach JT, Hempel S, Lynch SV, Sanders ME and Tancredi DJ: Guide to designing, conducting, publishing and communicating results of clinical studies involving probiotic applications in human participants. Gut Microbes 1: 243-253, 2010.